Wiserscope Medical Completes Tens of Millions RMB Series A First-Tranche Financing Led by Lvhe Investment

VCBeat has exclusively learned that, recently,Guangzhou Wiserscope Co., Ltd.(hereinafter referred to as “Wiserscope Optoelectronics) announced the completion of its first tranche of Series A financing, amounting to tens of millions of RMB. This round was led byGreenriver InvestmentExclusive Investment,Lingshan CapitalServing as the exclusive financial advisor. The proceeds from this financing round will be primarily used to increase investment in research and development, expand production facilities to enhance capacity, and further strengthen process engineering, technological capabilities, and supply chain reliability, thereby consolidating the company’s leading position in the critical segment of the electronic endoscopy core supply chain.

Guangzhou Wiserscope Co., Ltd., established in March 2019, specializes in the R&D and manufacturing of core components such as medical electronic endoscope camera modules and semi-finished medical electronic endoscopes. The company provides R&D and contract development and manufacturing organization (CDMO) services for medical image processors and finished electronic endoscopes, as well as packaging and testing services for ultra-miniature medical sensors (e.g., temperature and pressure sensors). It is recognized as a National High-Tech Enterprise, a Guangdong Province “Specialized, Refined, Differential, and Innovative” SME, and a Guangdong Province Innovative SME.

In Q4 2020, Wiserscope completed its angel financing round of nearly RMB 10 million, invested by Guangzhou Jinjue Capital. In Q3 2021, the company secured tens of millions of RMB in its Pre-A financing round, led by Shanlan Capital, with participation from Bangming Capital and Qianhai Great Wall. In Q3 2022, Wiserscope closed its Pre-A+ financing round, exclusively invested by Guanghua Venture Capital, an affiliate of the Tsinghua Pearl River Delta Research Institute.

Past Few YearsWiserscopeRapid growth has been achieved by assembling a highly experienced R&D team, commissioning over 1,000 square meters of GMP-compliant cleanroom facilities, establishing an ISO 13485 quality management system, and implementing information systems such as ERP, MES, and PLM. By leveraging self-developed equipment to automate core processes and enable comprehensive image evaluation capabilities, and by integrating upstream and downstream resources, the company has facilitated the rapid development of China’s disposable medical endoscope industry.

Currently, Wiserscope is actively expanding its overseas market and made its debut at MEDICA 2023, the medical equipment exhibition held in Düsseldorf, Germany. In 2024, Wiserscope will remain true to its original aspiration and forge ahead with determination.

WiserscopeStated: "First of all, we sincerely appreciate the trust and strong support from Shanghai Greenriver Investment Co., Ltd., as well as the dedication and efforts contributed by BITOLA CAPITAL in this round of financing. Guangzhou Wiserscope Co., Ltd. will remain committed to its corporate strategy of being a 'leading supporting player'."”positioning, serving customers in the fields of medical electronic endoscopes, surgical robots, and other active sterile high-value consumables, with the support of capital and upstream partners.

Greenriver InvestmentIt was stated that with the rapid development of clinical diagnosis and treatment, the development of minimally invasive interventional devices has become increasingly refined and intelligent, making product design and development more technically demanding and challenging for device companies. Meanwhile, the normalization of health insurance cost containment requires device companies to balance cost and efficiency in product development. Guangzhou Wiserscope Co., Ltd. has been focusing on developing core components and efficient process solutions for minimally invasive interventional devices, serving device companies from the upstream supply chain level. This enables device companies to better leverage their strengths, concentrate on product design and R&D, and bring highly competitive medical devices to domestic and international markets. We highly recognize the pragmatic work style and continuous innovation and R&D capabilities of the Guangzhou Wiserscope team, and look forward to Guangzhou Wiserscope contributing greater strength to the medical device industry.

Shanghai Greenriver Investment Co., Ltd. was established in 2007 and is an investment management firm specializing in early-stage venture capital. The company manages nine registered funds with a cumulative asset scale exceeding RMB 5 billion. The capital for these funds is primarily sourced from the company’s own funds, entrepreneurs of portfolio companies, and government guidance funds. The company’s main investment sectors include healthcare, new materials, pan-semiconductors, and high-end equipment manufacturing, having invested in more than 60 innovative companies to date. By proactively aligning with national strategies and making early investments in emerging industries, the company contributes to China’s economic transformation and development. It was recognized as one of the Top 30 Early-Stage Venture Capital Firms in China by VCBeat in both 2021 and 2022.